Fig. 3

a: Quantitative HBV RNA at baseline yields a high NPV for HBeAg seroconversion. Analysis yielded an NPV of 77.8% for HBV RNA > 200,000 copies/mL at baseline; b: Positive predictive value (PPV) of HBV RNA at week 12 as a predictor of HBeAg seroconversion. Analysis yielded a PPV of 75.0% for HBV RNA ≤ 3000 copies/mL, of whom 17.1% achieved HBeAg seroconversion yielding a NPV of 82.9%. c: Serum HBV RNA at week 24 yielded a PPV of 70.6% and NPV of 77.3% for predicting HBeAg seroconversion. d: Serum HBV RNA at baseline and week 12 of treatment relationship to HBeAg seroconversion: Among patients with HBV RNA ≦ 200,000 copies/mL at baseline and ≦ 3000 copies/mL at week 12, 92.9% achieved a response. However, the rates of response among patients with HBV RNA > 200,000 copies/mL at baseline and > 3000 copies/mL at week 12, only 12.5%. HBV RNA, hepatitis B ribonucleic acid (copies/mL). e: Among patients with HBV RNA ≦ 3000 copies/mL and HBsAg ≦ 4000 IU/mL at week 12, 66.7% achieved a response. Whereas, the rates of response among patients with HBV RNA > 3000 copies/mL and HBsAg ≦ 4000 IU/ Ml at week 12, only 3.7% patients achieved a response. HBV RNA, hepatitis B ribonucleic acid (copies/mL)